A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Summary
Approximately 1-2% of the population is affected by bipolar disorder—sometimes known as manic-depression. The symptoms come in two phases, one marked by a depressed mood, loss of pleasure, and sleeping problems; the other includes increased energy, racing thoughts, and a decreased need for sleep.
This study is evaluating the effect of an investigational medication on mood compared to a placebo in people with Bipolar Disorder currently suffering from depression. A “placebo” is a medication that looks like the active medication, but does not contain any active ingredients.
How Can You Qualify?
Research physicians at Scranton Medical Institute are seeking people 18 years old and over with Bipolar Disorder, Type I, who are currently experiencing a depressed state. All study related visits, laboratory work, study medication, meals on assessment days, and all study related procedures are provided at no cost. Qualified participants will receive at no cost; study related physical exams, study medication, study-related laboratory tests and compensation for time and travel.
Principal Investigator
AC Patel, MD
Contact
Mark Schrier
-
(570) 207-3945
or
mschrier@gminstitutes.com
Location
Scranton Medical Institute - Scranton, Pennsylvania
